Elisabetta Dejana was born in Bologna, where she graduated. She worked as post doc in Canada, at Mc Master University in Hamilton and at Mario Negri Institute in Milan where she directed the Vascular Biology lab. From 1993 to 96 she moved to Grenoble, (France) to direct an INSERM Unit and CEA Laboratory at the Center of Nuclear Energy (CENG). She then returned to Milan to take part in the creation of a new research institute supported by the Italian Foundation for Cancer Research (FIRC Institute of Molecular Oncology). More recently, she opened a new laboratory at the Department of Immunology, Genetics and Pathology at the Uppsala University, Sweden. Elisabetta dedicated her work to the study of vascular biology both in embryo development and in pathological conditions. During her research activity she made major contributions to the characterization of the structure and function of endothelial cell-to-cell junctions. These structures play a crucial role in the maintenance of vascular integrity, in the control of vascular permeability and tumor angiogenesis. Elisabetta is the author of more of 400 research articles published in international Journals, she received two “Laurea Honoris Causa” at the University of Frankfurt and Helsinki, she has been nominated “Honorary Officer of the Italian Republic” and won several international prizes for her research career including the prestigious Lefoulon-Delalande prize.
Nicolas L’Heureux holds a Bachelor’s degree in Biochemistry, a Master’s degree in Immunology and Microbiology, and a Ph.D. in Molecular and Cell Biology from the Laval University in Quebec City, Canada. He completed his training as a post-doctoral fellow of the American Heart Association at the Bioengineering Department at UCSD. In 2000, he co-founded Cytograft Tissue Engineering, Inc. (San Francisco) where he held the position of Chief Scientific Officer for 15 years. He joined the INSERM (French Institute of Health and Medical Research) in 2015 as a Research Director at the Laboratoire de Bioingénierie Tissulaire (U1026), or BioTis, at the University of Bordeaux. Dr. L’Heureux has raised over 20 M$ in private funding and won seven NIH grants. He is the recipient of a chair from the Excellence Initiative of Université de Bordeaux (IdEx) as well as an ANR grant. Dr. L’Heureux has been an early believer in the possibility of developing completely biological tissue engineering approaches to produce constructs with physiological biomechanical properties. At a time when synthetic scaffolds were seen as a defining part of any tissue engineered construct, he demonstrated that the cell-assembled extracellular matrix (CAM), produced by normal human cells in vitro, can be used to create completely biological, living, autologous and human tissues that display remarkable mechanical strength without the need for any exogenous scaffolding. Dr. L’Heureux has focused most of his efforts on developing autologous small diameter blood vessels. During his years at Cytograft Tissue Engineering, Dr. L’Heureux has sought to accelerate the translation of this technology to the clinic. This effort has led to the first clinical use of tissue-engineered blood vessels under arterial pressure and demonstration on long-term durability. Recent clinical data have also shown the possibility of using allogeneic CAM. Current efforts focus on the development of textile-based approaches to assemble threads of CAM into blood vessels.
Le Pr Fabrizio Andreelli est diabétologue et a effectué ses études de médecine à la Faculté de Médecine Pierre et Marie Curie à Paris, sur le site du CHU Pitié-Salpêtrière. Durant son clinicat, il a travaillé pendant 6 ans à Lyon, à l’Hôpital Edouard Herriot où il a pu apprendre les méthodes d’exploration du métabolisme des glucides et des lipides chez l’homme au centre de recherche en nutrition humaine (CRNH de Lyon) dirigé par le Pr Martine Laville. Puis, il a travaillé sur divers modèles de souris au métabolisme glucidique perturbé à l’Institut Cochin, dans le laboratoire dirigé par le Pr Axel Kahn. Il a ensuite été nommé Maître de Conférences des Universités-Praticien Hospitalier puis Professeur des Universités-Praticien Hospitalier dans le service de Diabétologie-Nutrition du CHU Bichat Claude Bernard à Paris où il a exercé les fonctions de référent en nutrition, en particulier pour le suivi des patients ayant bénéficié d’une chirurgie bariatrique dont il a étudié de nombreux effets. Pour mieux comprendre la guérison du diabète de type 2 souvent observée après la chirurgie chez l’homme, il a créé le premier modèle murin de chirurgie bariatrique en France et poursuit actuellement ses travaux sur les modifications du pancréas après la chirurgie bariatrique dans le service de Diabétologie du CHU Pitié-Salpêtrière à Paris et dans l’unité INSERM U1166 à la faculté de médecine Pierre et Marie Curie dans le groupe du Pr Karine Clément.
Florian Kronenberg, MD is specialized in Medical Genetics and is a Full Professor for Genetic Epidemiology and Head of the Division of Genetic Epidemiology at the Medical University of Innsbruck.
After his training in Medical Genetics at Gerd Utermann's laboratory at the University of Innsbruck, Florian Kronenberg worked with Roger R. Williams and Steve Hunt at the Department of Cardiovascular Genetics at the University of Utah, USA. Later, he was the head of the Research Unit "Genetic Epidemiology" at the Institute of Epidemiology, at the Helmholtz Center Munich (former GSF). In 2004, he became full professor and head of the Division of Genetic Epidemiology at the Innsbruck Medical University.
Florian Kronenberg served as principal investigator in several studies on genetic risk factors for atherosclerosis and biomarkers for the progression of chronic kidney disease including the "Mild to Moderate Kidney Disease Study" (MMKD) and is a Co-PI of the “German Chronic Kidney Disease” (GCKD) study. He was a workgroup member of the NKF K/DOQI Guidelines on "Cardiovascular Disease in Dialysis Patients" and the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. He has published roughly 350 papers and his research interests are genetic and clinical epidemiological studies on lipoprotein(a) as well as genetics of complex diseases such as atherosclerosis, kidney diseases, diabetes mellitus and related intermediate phenotypes.